bioRxiv · 10.1101/2024.10.10.617689
Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes
Abstract
Antimicrobial resistance (AMR) poses a fundamental global threat, necessitating new strategies for effective therapies. Cystobactamids (CYS), a class of antibacterial agents targeting bacterial gyrase and topoisomerase IV, represent a non-traditional chemical scaffold with broad-spectrum activity. For toxicological de-risking, we performed a comprehensive profiling on eukaryotic cells, focusing on cytotoxicity, genotoxicity, and mitochondrial toxicity, demonstrating cellular safety and superoxide scavenging properties. Studies in zebrafish embryos assessed developmental, cardiovascular, and hepatic toxicity, indicating a favorable in vivo safety profile. Metabolism studies revealed glucuronidation and amide bond hydrolysis as key pathways, whereby CYS metabolic stability substantially improved by cobicistat co-treatment. Affinity-based protein profiling identified the cholesterol- and HCV-receptor scavenger receptor class B member 1 (SCARB1) as a primary eukaryotic off-target protein, with cystobactamids shown to inhibit SCARB1s function, preventing hepatitis C virus pseudoparticle entry into cells. These findings suggest a high therapeutic potential for cystobactamids and highlight SCARB1 as a primary eukaryotic target.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Risch, T., Hellwinkel, B., Mostert, D., Kany, A. M., Solga, D., Seedorf, T., Heimann, D., Hoppstädter, J., Kohnhäuser, D., Hilgers, J.-S., Fries, F., Deschner, F., Brönstrup, M., Kirschning, A., Sieber, S. A., Pietschmann, T., Kiemer, A. K., Herrmann, J., Müller, R.. 2024-10-17. Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes. https://doi.org/10.1101/2024.10.10.617689
Cite the original work for its findings. Save a collection to share your selection of sources.